| Literature DB >> 20211803 |
Elissa H Wilker1, Andrea Baccarelli, Helen Suh, Pantel Vokonas, Robert O Wright, Joel Schwartz.
Abstract
BACKGROUND: Black carbon (BC) is a marker of traffic pollution that has been associated with blood pressure (BP), but findings have been inconsistent. MicroRNAs (miRNAs) are emerging as key regulators of gene expression, but whether polymorphisms in genes involved in processing of miRNAs to maturity influence susceptibility to BC has not been elucidated.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20211803 PMCID: PMC2920913 DOI: 10.1289/ehp.0901440
Source DB: PubMed Journal: Environ Health Perspect ISSN: 0091-6765 Impact factor: 9.031
Descriptive statistics at baseline for participants included in analysis (n = 789).a
| Study characteristic | Value |
|---|---|
| BP measurements | |
| SBP (mmHg) | 132.0 ± 18.4 |
| DBP (mmHg) | 76.8 ± 10.9 |
| Clinical measures | |
| Age at visit (years) | 72.3 ± 7.5 |
| BMI (kg/m2) | 28.0 ± 4.1 |
| Pulse (beats/min) | 71.1 ± 8.1 |
| Hypertension diagnosis | 542 (81.8) |
| Hypertension medication use | 478 (72.1) |
| Two or more drinks per day | 199 (25.2) |
| Diabetes | 182 (23.1) |
| Education (years) | |
| ≤ 12 | 280 (35.5) |
| 13–16 | 372 (47.2) |
| > 16 | 137 (17.3) |
| Smoking status | |
| Never | 237 (30.0) |
| Current | 47 (6.0) |
| Former | 505 (64.0) |
| Air pollution and weather data | |
| Seven-day moving average BC (μg/m3) | 0.98 ± 0.415 |
Values are mean ± SD or no. (%).
A total of 2,349 observations (one to six study visits) from 789 NAS participants were included in these analyses.
Diabetes was classified as physician-diagnosed diabetes mellitus or fasting blood glucose > 126 mg/dL.
Linear mixed-effects models estimating the change in BP associated with a 1-SD increasea in BC.b
| Model 1 | Model 2 | |
|---|---|---|
| SBP | 3.52 (2.77–4.26) | 3.04 (2.29–3.79) |
| DBP | 2.72 (2.31–3.12) | 2.28 (1.88–2.67) |
Corresponding to a 0.415-μg/m3 increase in 7-day average BC concentrations.
A total of 2,349 observations from 789 NAS participants were included in these analyses.
Model 1 was adjusted for age, BMI, smoking status, season, 7-day moving average of BC, and 7-day moving average of apparent temperature.
Model 2 was adjusted for education, blood urea nitrate, age, BMI, pulse, smoking status, pack-years, median income, apparent temperature, alpha blocker use, beta blocker use, calcium channel blocker use, angiotensin receptor blocker use, ACE inhibitor use, diuretics, season, two or more drinks per day, and diabetes diagnosis.
SNPs in miRNA processing genes included in analysis.
| Gene | RS number | SNP position | Alleles | Role | Amino acid change | MAF (%) |
|---|---|---|---|---|---|---|
| Gem-associated protein 3 | rs197414 | chr1:112110646 | C/A | Coding exon | Arginine/serine | 0.12 |
| rs197388 | chr1:112099005 | T/A | Promoter | 0.18 | ||
| rs197412 | chr1:112110476 | T/C | Coding exon | Isoleucine/threonine | 0.38 | |
| rs595961 | chr1:36140367 | A/G | Intron | 0.15 | ||
| rs6877842 | chr5:31568395 | G/C | Promoter | 0.18 | ||
| Exportin 5 ( | rs11077 | chr6:43598925 | C/A | 3′ UTR | 0.40 | |
| rs4961280 | chr8:141716596 | C/A | Promoter | 0.18 | ||
| Tar-RNA binding protein 2 ( | rs784567 | chr12:52180732 | C/T | Promoter | 0.49 | |
| rs13078 | chr14:94626500 | T/A | 3′ UTR | 0.18 | ||
| Gem-associated protein 4 ( | rs7813 | chr17:594936 | T/C | Coding exon | Cysteine/arginine | 0.43 |
| rs1062923 | chr17:595817 | T/C | Coding exon | Isoleucine/threonine | 0.19 | |
| rs3744741 | chr17:595982 | C/T | Coding exon | Arginine/glutamine | 0.11 | |
| rs4968104 | chr17:596255 | T/A | Coding exon | Valine/glutamic acid | 0.27 | |
| rs910925 | chr17:596297 | G/C | Coding exon | Glycine/alanine | 0.42 | |
| rs2740348 | chr17:596685 | G/C | Coding exon | Glutamic acid/glutamine | 0.15 | |
| rs910924 | chr17:602670 | C/T | Promoter | 0.27 | ||
| DiGeorge syndrome critical region gene 8 | rs3757 | chr22:18479331 | G/A | 3′ UTR | 0.25 | |
| rs1640299 | chr22:18478359 | G/T | 3′ UTR | 0.48 | ||
| Ras-related nuclear protein | rs14035 | chr12:129927194 | C/T | 3′ UTR | 0.28 |
Abbreviations: HWE, Hardy–Weinberg equilibrium; MAF, minor allele frequency; RS, reference SNP.
Gene name (abbreviation), official gene symbol.
HWE p = 0.08.
HWE p = 0.05.
Effect modification of the association between a 1-SDa increase in BC concentrations and BP by gene variants related to miRNA processing under recessive models.b
| Sensitivity analyses | |||||
|---|---|---|---|---|---|
| Results Δ mmHg (95% CI) | Model 2 | Model 1 | IPW | ||
| DBP | |||||
| Wild-type and heterozygotes | 590 | 2.57 (2.12 to 3.02) | 0.006 | 0.002 | 0.004 |
| Homozygous carriers | 189 | 1.48 (0.78–2.18) | |||
| Wild-type and heterozygotes | 738 | 2.32 (1.91 to 2.72) | 0.017 | 0.03 | 0.008 |
| Homozygous carriers | 25 | 0.13 (−1.65 to 1.91) | |||
| Wild-type and heterozygotes | 638 | 2.44 (2.00 to 2.87) | 0.02 | 0.04 | 0.006 |
| Homozygous carriers | 136 | 1.40 (0.60 to 2.21) | |||
| Wild-type and heterozygotes | 647 | 2.44 (2.02 to 2.87) | 0.024 | 0.04 | 0.006 |
| Homozygous carriers | 134 | 1.43 (0.61 to 2.25) | |||
| SBP | |||||
| Wild-type and heterozygotes | 769 | 3.07 (2.32 to 3.82) | 0.005 | 0.01 | 0.01 |
| Homozygous carriers | 10 | −9.82 (−18.68 to −0.95) | |||
| Wild-type and heterozygotes | 739 | 2.87 (2.10 to 3.65) | 0.045 | 0.04 | 0.027 |
| Homozygous carriers | 37 | 5.58 (3.01 to 8.14) | |||
A 1-SD increment in BC concentration is equal to 0.415 μg/m3.
Adjusted for age (years), BMI, cigarette smoking status (never, current, former), pack-years smoked, blood urea nitrate, type 2 diabetes diagnosis, two or more alcoholic drinks per day, and current antihypertensive medication use (including angiotensin II receptor-, alpha-adrenoceptor, beta- or calcium channel blockers, diuretics, or ACE inhibitors) as well as apparent temperature, and season of clinical visit (spring: March–May; summer: June–August; autumn: September–November; winter: December–February).
Two-sided p-value for interaction from SNP-by-BC coefficient.
p-Value for interaction from SNP-by-BC coefficient for sensitivity analysis using IPW.
Figure 1Major steps in miRNA processing. Long primary transcripts coded within the introns of protein-coding genes are transcribed into primary miRNAs (pri-miRNAs). Then DROSHA and the DGCR8 complex mediate the formation of the pre-miRNA stem-loop. After export from the nucleus via the RAN-GTP complex and Exportin5, these pre-miRNAs undergo modification by DICER within the cytoplasm to generate an ~ 22-nt duplex from the loop complex, which comprises the miRNA and its complement. AGO2, GEMIN3, and GEMIN4 then interact with miRNA to form a ribonucleoprotein that guides the miRNA into the RISC, where the miRNA strand anneals to the 3′ UTRs of target mRNAs, promoting translational repression or mRNA degradation.